Spinal cord · 2026
Effect of methylprednisolone in cervical spinal cord injury stratified by injury severity: analysis in 908 patients.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mimura Tetsuhiko, Moghaddamjou Ali, Badhiwala Jetan H, Vaccaro Alexander R, Shaffrey Christopher I, Harrop James S, Guest James D, Aarabi Bizhan, Fehlings Michael G
Аннотация
STUDY DESIGN: Cohort study.
OBJECTIVES: Although the effectiveness of methylprednisolone sodium succinate (MPSS) in spinal cord injury (SCI) is controversial, it is hypothesized that the effectiveness and safety profile of MPSS may vary in select cervical SCI sub-populations. The objective of this study is to clarify the effect of MPSS and its impact on adverse events in patients with cervical SCI, stratified by baseline neurological status.
SETTING: Three large prospective, multicenter data sets of patients with acute SCI.
METHODS: Patients with acute cervical SCI were enrolled. The primary outcomes were upper extremity motor scores (UEMS) and lower extremity motor scores (LEMS) at 1 year. Patients were grouped by baseline American Spinal Injury Association Impairment Scale (AIS) grade.
RESULTS: 908 patients meeting inclusion criteria were analyzed. In AIS grade A patients, the use of MPSS resulted in significantly improved LEMS (mean difference [MD], 3.0; 95% CI, 0.3-5.6; p = 0.02), but not UEMS (MD, 0.5; 95% CI, -2.5-3.5; p = 0.74), at 1 year. In contrast, no significant benefit was observed in patients with AIS grades B, C, or D. In AIS grade A patients, the MPSS group had a lower incidence of cardiopulmonary adverse events (42.5 vs. 62.8%; p < 0.001) and gastrointestinal/genitourinary adverse events (13.7 vs. 22.4%; p = 0.04).
CONCLUSIONS: MPSS was associated with improved lower extremity motor recovery in AIS grade A cervical SCI patients. No significant effect was seen in patients with incomplete injuries. MPSS was not associated with an overall increase in adverse events, suggesting it may be selectively beneficial in severe cervical SCI.
OBJECTIVES: Although the effectiveness of methylprednisolone sodium succinate (MPSS) in spinal cord injury (SCI) is controversial, it is hypothesized that the effectiveness and safety profile of MPSS may vary in select cervical SCI sub-populations. The objective of this study is to clarify the effect of MPSS and its impact on adverse events in patients with cervical SCI, stratified by baseline neurological status.
SETTING: Three large prospective, multicenter data sets of patients with acute SCI.
METHODS: Patients with acute cervical SCI were enrolled. The primary outcomes were upper extremity motor scores (UEMS) and lower extremity motor scores (LEMS) at 1 year. Patients were grouped by baseline American Spinal Injury Association Impairment Scale (AIS) grade.
RESULTS: 908 patients meeting inclusion criteria were analyzed. In AIS grade A patients, the use of MPSS resulted in significantly improved LEMS (mean difference [MD], 3.0; 95% CI, 0.3-5.6; p = 0.02), but not UEMS (MD, 0.5; 95% CI, -2.5-3.5; p = 0.74), at 1 year. In contrast, no significant benefit was observed in patients with AIS grades B, C, or D. In AIS grade A patients, the MPSS group had a lower incidence of cardiopulmonary adverse events (42.5 vs. 62.8%; p < 0.001) and gastrointestinal/genitourinary adverse events (13.7 vs. 22.4%; p = 0.04).
CONCLUSIONS: MPSS was associated with improved lower extremity motor recovery in AIS grade A cervical SCI patients. No significant effect was seen in patients with incomplete injuries. MPSS was not associated with an overall increase in adverse events, suggesting it may be selectively beneficial in severe cervical SCI.